美股A股
StockGist
Back
8-K2026-05-07· deepseek-chat

HRMY · Harmony Biosciences Holdings, Inc.

0001104659-26-056786

SEC filing

Summary

Harmony Biosciences reported Q1 2026 WAKIX net revenue of $215.4M (17% YoY growth) and reiterated full-year 2026 net revenue guidance of $1.0B-$1.04B.

Key takeaways

Full analysis

Harmony Biosciences reported Q1 2026 net product revenue of $215.4 million for WAKIX, a 17% year-over-year increase from $184.7 million in Q1 2025. The growth was driven by continued strong demand, with average patients on WAKIX reaching 8,500 in Q1 and exiting at 8,600, despite seasonal market access headwinds that were more pronounced this year. The company reiterated its full-year 2026 net revenue guidance of $1.0 billion to $1.04 billion, reflecting confidence in the franchise's trajectory.

Net income declined to $32.5 million ($0.55 per diluted share) from $45.6 million ($0.78) in the prior year, primarily due to $32.0 million in upfront payments for license agreements entered into during Q1 2026, which had an after-tax impact of $0.45 per share. Cost of product sold increased to 20.7% of net revenue from 17.3%, driven by new royalties from the Novitium license agreement. Total operating expenses rose 38% to $133.6 million, largely from the license-related R&D expenses.

Management highlighted four strategic pillars: protecting the pitolisant franchise through IP (6 of 7 ANDA settlements, new lawsuit against AET Pharma/Sandoz), continued growth via lifecycle management (Pitolisant GR NDA on track for Q2 2026, Pitolisant HD Phase 3 data in 2027), advancing the pipeline (BP-205 Phase 1 data mid-2026, EPX-100 Phase 3 enrolling), and renewed emphasis on business development targeting 2028-2032 revenue opportunities. The company ended Q1 with $870.5 million in cash, providing significant capacity for transactions.

Personnel updates include the appointment of Peter Anastasiou as COO (effective April 2, 2026) and Glenn Reicin as CFO (effective April 14, 2026), supporting the next phase of growth.